The premier event in malignant & non-malignant hematology, the annual meeting of the American Society for Hematology provided an exciting amount of new research to the forefront. Read the main article to hear some of the event highlights in addition to the research spotlight below.
Northstar Study – Demonstrated that gene therapy can help patients with beta-thalassemia major reduce or eliminate their dependence on transfusions.
Sickle cell disease Study - Oral medication can be a good alternative to transfusion in patients with sickle cell anemia and a high risk of stroke, as indicated by Transcranial Doppler (TCD) screening.
Phase III Tourmaline-MM1 Study - Found positive outcomes after adding Ixazomib, an oral proteasome inhibitor, to standard care with lenalidomide (Revlimid) and dexamethasone.
Phase I/II Daratumumab Study - A human anti-CD38 IgG1κ monoclonal antibody provides good response it is combined with lenalidomide and dexamethasone.
ASH Meeting: Event Program
Happy 50th Anniversary Flow Cytometry!
Flow cytometry, which allows for measurement of multiple parameters and rapid analysis of individual cells within a liquid sample, has become a staple for biological research as well as clinical diagnostics. The number of simultaneous measurements that can be done on each cell has grown to more than 30, leading to a wealth of scientific data. Flow cytometry is now an industry worth more than $3 billion and its use has expanded into environmental sciences and the livestock industry. Get a glimpse into a pioneer in the field as he reflects on the history and future of flow cytometry.
Original Abstract: Flow cytometry strikes gold